Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Alternative Names: Men Quad TT; MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; TetraMen-T

Latest Information Update: 08 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Conjugate-vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 10 Oct 2018 Phase-III clinical trials inMeningococcal group A infections, Meningococcal group C infections, Meningococcal group W-135 infections and Meningococcal group Y infections (In infants, Prevention) in United Kingdom (IM) (NCT03632720)
  • 04 Oct 2018 Sanofi Pasteur initiates enrolment in a phase III trial for Meningococcal groups A, C, Y, W-135 infections (In infants, Prevention) in USA (IM) (NCT03691610)
  • 03 Oct 2018 Immunogenicity and adverse events data from a phase III trial in Meningococcal group A infections presented at the IDWeek (IDW-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top